Age is a prevalent prognostic factor to take into consideration when choosing acute lymphoblastic leukemia (ALL) treatment. Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, highlights the different treatment options available such as kinase inhibitors, chemotherapy, transplant and immunotherapeutic agents. He further talks about the difficulties of maintaining remission and how to overcome these issues. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).